FDA
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
-
-
-
-
-
-
-
Zentalis selects 400mg dose for azenosertib ovarian cancer trials
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Zentalis Pharmaceuticals (ZNTL)
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $20 at H.C. Wainwright
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
-
326,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

